Minireviews
Copyright ©The Author(s) 2024.
World J Gastrointest Oncol. Apr 15, 2024; 16(4): 1166-1179
Published online Apr 15, 2024. doi: 10.4251/wjgo.v16.i4.1166
Figure 6
Figure 6 Metastatic treatments recommendations. NET: Neuroendocrine tumours; NEC: Poorly differentiated neuroendocrine cancers; Non-NE: Non-neuroendocrine; M: Month; 1L: First line treatment; 2L: Second line treatment; FOLFIRI: Irinotecan plus 5-fluorouracil; CAPTEM: Capecitabine plus temozolamide; BV: Bevacizumab; STZ: Streptozocin; MMR: Mismatch repair; SSTR-5: Expression of somatostatin receptor type 5; PRRT: Radiotherapy with radionuclides; AS: Somatostatin anologues; FOLFOX: Oxaliplatin plus 5-fluorouracil.